Clinical Trials on Hepatic Fibrogenesis in United States

Total 967 results

University of Wisconsin, Madison

Completed

Impact of Moderate Alcohol Use on Hepatitis C Virus (HCV) Progression

Hepatitis C | Hepatic Fibrogenesis

United States
GlycoMimetics Incorporated

Completed

A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

Moderate Hepatic Impairment | Normal Hepatic Function

United States
Novartis Pharmaceuticals

Completed

Evaluation of Hepatic Function Impairment on the Pharmacokinetics of LEE011

Normal Hepatic Function | Impaired Hepatic Function

United States
Novartis Pharmaceuticals

Completed

Effect of Hepatic Impairment on LDK378 Pharmacokinetics

Normal Hepatic Function | Impaired Hepatic Function

United States
Novartis Pharmaceuticals

Completed

Effect of Hepatic Impairment on LDE225..

Normal Hepatic Function | Impaired Hepatic Function

Belgium, Germany, Israel, Bulgaria, United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Effects of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine

Hepatic Impairment | Normal Hepatic Function

United States
Pfizer

Recruiting

A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction

Healthy Volunteers | Moderate Hepatic Impairment | Severe Hepatic Impairment

United States
Takeda

Completed

Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment

Severe Hepatic Impairment

United States
Bausch Health Americas, Inc.

Terminated

Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects

Severe Hepatic Impairment

United States
Shire

Completed

Pharmacokinetics (PK) of 20 mg Teduglutide in Participants With Moderately Impaired Hepatic Function Compared to Healthy Participants

Hepatic Impairment

United States
Pfizer

Completed

Evaluate Severe Hepatic Impairment on Dacomitinib PK

Severe Hepatic Impairment

United States
Agios Pharmaceuticals, Inc.

Completed

A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function

Moderate Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetic Study of Icenticaftor in Participants With Hepatic Impairment

Hepatic Failure

United States
Daiichi Sankyo, Inc.

Completed

A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment

Hepatic Impairment | Moderate Impaired Hepatic Function

United States
University of Michigan Rogel Cancer Center

Completed

Assessment Of Liver Function in Patients Undergoing Hepatic Irradiation (IC-Green)

Hepatic Irradiation

United States
AdventHealth

Completed

Endoscopic Ultrasound Guided Liver Biopsy

Hepatic Cancer | Hepatic Carcinoma | Hepatic Neoplasm

United States
Biotie Therapies Inc.
Acorda Therapeutics

Terminated

Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant

Hepatic Impairment

United States
Pfizer

Completed

A Study To Describe The Effect Of Impaired Hepatic Function Of The Pharmacokinetics Of Palbociclib

Healthy, Hepatic Insufficiency

United States
Case Comprehensive Cancer Center

Completed

Comparison of Yttrium-90 Absorbed Doses Using PET/CT Versus PET/MR Imaging for Hepatic Malignancies

Hepatic Malignancies

United States
Eisai Inc.

Completed

A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)

Hepatic Impairment | Hepatic Function

United States
Merck Sharp & Dohme LLC

Completed

Belzutifan (MK-6482) Hepatic Impairment Study (MK-6482-020)

Moderate Hepatic Impairment

United States
Jazz Pharmaceuticals

Completed

Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients

Hepatic Impairment

United States
M.D. Anderson Cancer Center

Recruiting

Stereotactic Liver Ablation Assisted With Intra-Arterial CT Hepatic Arteriography and Ablation Confirmation Software Assessment (STEREOLAB)

Liver Ablation | Hepatic

United States
BeiGene

Completed

Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver Function

Hepatic Insufficiency & Healthy Subjects

United States
Pfizer
Medivation, Inc.

Completed

Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [Pf-01913539] In Subjects With Hepatic Impairment And Normal Hepatic Function

Hepatic Failure

United States
The University of Texas Medical Branch, Galveston

Terminated

Evaluation of Mechanisms Responsible for Coma in Patients Affected by Fulminant, Acute and Chronic Hepatic Failure

Acute and Chronic Hepatic Failure With Developing Coma

United States
KBP Biosciences
Covance

Completed

Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment

Healthy | Moderate Hepatic Impairment

United States
The University of Texas Health Science Center at...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Active, not recruiting

Empagliflozin and Hepatic Glucose Metabolism

Hepatic Glucose Metabolism

United States
Atea Pharmaceuticals, Inc.

Recruiting

Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function

Hepatic Impairment | Healthy Volunteer

United States
AstraZeneca

Completed

Open-label Study to Assess the Pharmacokinetics of NKTR-118 in Patients With Impaired Hepatic Function

Hepatic; Functional Disturbance

United States
Genfit

Completed

Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients

Liver Diseases | Moderate Hepatic Impairment | Severe Hepatic Impairment

United States
EQRx International, Inc.

Completed

An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143

Severe Hepatic Impairment

United States
NGM Biopharmaceuticals, Inc

Completed

Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function

Impaired Hepatic Function

United States
Tetraphase Pharmaceuticals, Inc.

Completed

A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects

Impaired Hepatic Function

United States
Alexion

Recruiting

Study of ALXN2050 in Participants With Hepatic Impairment

Healthy | Impaired Hepatic Function

United States
Acerta Pharma BV
AstraZeneca

Completed

Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite

Hepatic Insufficiency | Healthy Subjects | Hepatic Impairment

United States
Daiichi Sankyo, Inc.

Completed

Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants

Moderate Hepatic Impairment

United States
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function

Mild and Moderate Hepatic Impairment

United States
Hunter Holmes Mcguire Veteran Affairs Medical Center
Instituto Grifols, S.A.; McGuire Research Institute

Completed

HEAL STUDY (Hepatic Encephalopathy and Albumin Study) (HEAL)

Hepatic Encephalopathy | Cirrhosis | Minimal Hepatic Encephalopathy | Covert Hepatic Encephalopathy

United States
Seagen Inc.

Completed

A Safety Study of Tucatinib in Healthy and Hepatically-Impaired Subjects

Hepatic Impairment

United States
Cardiox Corporation

Withdrawn

Cardiox Liver Function Test Pivotal Trial (LFT-0002)

Liver Failure | Hepatic Failure

United States
Vital Therapies, Inc.

Completed

Phase 2 Evaluation of the ELAD System in the Management of Acute Liver Failure

Fulminant Hepatic Failure

United States
Sanofi

Completed

Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Mild Hepatic Impairment Compared to Participants With Normal Hepatic Function

Hepatic Function Abnormal

United States, Belgium
UCB Biopharma S.P.R.L.

Terminated

A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function

Impaired Hepatic Function | Healthy Study Participants

United States
Vital Therapies, Inc.

Withdrawn

Safety and Efficacy of the Extracorporeal Liver Assist Device (ELAD®) In Patients With Fulminant Hepatic Failure (FHF) (ELAD)

Fulminant Hepatic Failure

United States
Nektar Therapeutics

Completed

A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol)

Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment

United States
Virginia Commonwealth University
National Center for Complementary and Integrative Health (NCCIH)

Completed

Probiotic Lactobacillus GG (LGG) in Patients With Minimal Hepatic Encephalopathy

Minimal Hepatic Encephalopathy

United States
Eli Lilly and Company
Loxo Oncology, Inc.

Completed

A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants

Healthy | Hepatic Impairment

United States
Indivior Inc.

Completed

Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects

Hepatic Impairment | Hepatic Failure | Chronic Hepatitis C Infection With Hepatic Coma

United States
Hunter Holmes Mcguire Veteran Affairs Medical Center
Bausch Health Americas, Inc.

Completed

Study of Rifaximin in Minimal Hepatic Encephalopathy

Minimal Hepatic Encephalopathy

United States

Clinical Trials on Hepatic Fibrogenesis in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uruguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations